69 results on '"Mu, Zhaomei"'
Search Results
2. Data from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
3. Supplementary Figure S1: Edelfosine and ADT inhibits cell proliferation in VCaP cells. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
4. Supplementary Figure S3: Temporal expression of p-AKT after AD and edelfosine treatment in LNCaP cells. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
5. Supplementary Figure S1: Edelfosine and ADT inhibits cell proliferation in VCaP cells. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
6. Supplementary Figure S4: ATF3 represses AR transcriptional target PSA expression in LNCaP cells after AD and edelfosine treatment. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
7. Supplementary Figure S5: Elevated ATF3 after AD and edelfosine treatments inhibits AR promoter activity in LNCaP cells. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
8. Supplementary Figure S2: ATF3 knockdown via siATF3 inhibits apoptosis in VCaP cells after AD and edelfosine treatment. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
9. Supplementary Figure Legends from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
10. Supplementary Figure S3: Temporal expression of p-AKT after AD and edelfosine treatment in LNCaP cells. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
11. Table S1 from Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells
12. Supplemental Table 1-3 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
13. Data from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
14. Data from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
15. Supplemental Table 1-3 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
16. Legends of Supplemental Figure 1-11 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
17. Supplementary Table S1. from Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer
18. Supplemental Figure 1-11 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
19. Supplemental Figure 1-11 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
20. Supplementary Table S2. from Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer
21. Supplementary Table S2. from Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer
22. Legends of Supplemental Figure 1-11 from CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
23. Supplementary Table S3. from Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer
24. Supplementary Table S3. from Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer
25. Supplementary Table S1. from Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer
26. Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer
27. Junctional Adhesion Molecules in Cancer: A Paradigm for the Diverse Functions of Cell–Cell Interactions in Tumor Progression
28. Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors
29. Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA
30. Abstract 2646: The liquid biopsy network in advanced breast cancer (ABC): Benchmarking the prognostic role of circulating tumor DNA (ctDNA) to the goal standard circulating tumor cells (CTCs) enumeration
31. Circulating tumor cells enumeration (CTCs) and circulating tumor DNA (ctDNA): Clinical and molecular features of “rapidly progressing” stage IV disease (Stage IVprog).
32. CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
33. Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer
34. Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells
35. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer
36. A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone
37. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer
38. Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer
39. Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
40. Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) longitudinal monitoring of metastatic breast cancer (MBC).
41. A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone (AP) for patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on abiraterone.
42. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer
43. Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells
44. The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study
45. Abstract 3232: CEP-37440, a highly selective and potent dual inhibitor of ALK and FAK1 inhibits the proliferation of inflammatory breast cancer cells
46. Abstract 2788: Comprehensive high-depth target sequencing in circulating tumor DNAs of patients with inflammatory and non-inflammation breast cancers
47. Abstract 384: Detection of circulating melanoma cells in paired arterial and venous specimens from uveal melanoma patients with hepatic metastatic
48. Abstract 224: Enrichment and isolation of uncontaminated breast cancer cells from human blood samples
49. Abstract P4-01-11: Circulating tumor cells (CTCs) detect HER2+ status and phenotypic heterogeneity in metastatic breast cancer (MBC)
50. Abstract P6-14-06: CCR5 antagonists suppresses the migration and invasion of human inflammatory breast cancer cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.